Rosuvastatin Suppresses the Oxidative Response in the Venous Limb of an Arteriovenous Fistula and Enhances the Fistula Blood Flow in Diabetic Rats

doi:10.1159/000357619

CNU IR > Pharmacy and Science > Dept. of Biotechnology (including master's program) > Periodical Articles > Item 310902800/28685

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/28685

Title:	Rosuvastatin Suppresses the Oxidative Response in the Venous Limb of an Arteriovenous Fistula and Enhances the Fistula Blood Flow in Diabetic Rats
Authors:	Fang, Shih-Yuan Roan, Jun-Neng Lin, Yu Hsu, Chih-Hsin Chang, Shih-Wei Huang, Chein-Chi Tsai, Yu-Chuan Lam, Chen-Fuh
Contributors:	生物科技系
Keywords:	HMG-CoA reductase inhibitors Inflammation Intimal hyperplasia Peripheral vascular diseases Superoxide Hennodialysis Arteriovenous shunt
Date:	2014
Issue Date:	2015-05-06 21:25:07 (UTC+8)
Publisher:	Karger
Abstract:	Objective:The blood flow in the arteriovenous (AV) fistula is significantly reduced in diabetic patients. Statins are known to mediate pleiotropic effects in the vascular endothelium and attenuate inflammatory responses. This study tested the vascular protective effect of rosuvastatin in an experimental model of AV fistula. Methods: One week after the induction of diabetes mellitus (DM) in rats, a fistula was created in the abdominal aorta and inferior vena cava. Rats received placebo or rosuvastatin (15 mg/kg/day) in chow for 2 weeks. The blood flow in the venous segments of the fistula was measured. The expression of proinflammatory genes and the generation of superoxide in the venous fistula were examined. Results: The blood flow and luminal diameter of the AV fistula was significantly enhanced in animals treated with rosuvastatin. Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. The levels of superoxide anions and proinflannmatory cytokines were also suppressed in rosuvastatin-treated animals. Neointinnal formation in the AV fistula was not affected following treatment with rosuvastatin. Conclusions: We demonstrated that rosuvastatin improves luminal dilatation and blood flow in the AV fistula of subjects with DM. These vascular protective effects of rosuvastatin are most likely mediated by the attenuation of proinflammatory activities in the remodeled vasculature. (C) 2014 S. Karger AG, Basel
Relation:	Journal of Vascular Research, v.51 n.2, pp.81-89
Appears in Collections:	[Dept. of Biotechnology (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1359	View/Open

Loading...